The MDS Beacon™

Leave a comment

News

Resources

Links

Most Recent Comments

• Norma: I am supposed to be put on Revlimid in about 3 weeks. My chrom. are normal so I don’t have 5q. My...
• Jeannie Kim: We have a patient starting on Vidaza IV daily x 5 days every 28 days regimen. The dose is 160mg (6.4...
• Biblia Kim: Dear Dr. Germing, Thank you for answering our reader’s question and for posting your reply directly on...
• ULrich Germing, MD: Dear Darlene, yes of course you should be tested for del(5q), because if you had del(5q) not only...
• Julie Shilane: Mr. Prieto, in NICE’s final draft guidance, which was released on Wednesday, the agency did not...

Subscribe

• Subscribe to our RSS feed
• Get Beacon News by Email
• Become our fan on Facebook!
• Follow us on Twitter!

News Archives

• ▼2010 (16)
  • ▼ March (3)
    • Trisomy 11 In Myelodysplastic Syndromes May Be An Indicator Of Higher-Risk MDS And Shorter Survival
    • Beacon NewsFlashes — March 5, 2010
    • Nplate May Be Effective In Treating Thrombocytopenia In Myelodysplastic Syndromes Patients
  • ► February (6)
    • Caring For A Loved One With Myelodysplastic Syndromes – Part 1: Making Your Own Health A Priority
    • Exjade Not Recommended For High-Risk Myelodysplastic Syndromes Patients
    • Recombinant Erythropoietin Alpha Without Granulyte-Colony Stimulating Factor Produces Longer Survival In Myelodysplastic Syndromes Patients
    • Study Shows Successful Stem Cell Transplantation For Elderly Myelodysplastic Syndromes Patients Depends On Disease Stage, Not Age
    • Molecular Analysis May Explain Why Dacogen Alone And Dacogen Plus Valproic Acid Show Similar Response Rates (ASH 2009)
    • Vidaza and Enbrel Combination Therapy May Improve Response In Myelodysplastic Syndromes Patients
  • ► January (7)
    • Beacon NewsFlashes - January 27, 2010
    • Vidaza and Thalidomide Combination Therapy Shows No Unexpected Side Effects In Myelodysplastic Syndromes Patients (ASH 2009)
    • Vidaza May Be Safe And Effective In MDS Patients Of All Ages (ASH 2009)
    • Dacogen Is Safe And Effective In Older Myelodysplastic Syndromes Patients (ASH 2009)
    • Vidaza and Thalidomide Combination Therapy Is Safe And At Least As Effective As Vidaza Alone In Myelodysplastic Syndromes Patients
    • Researchers Observe High Survival Time For Myelodysplastic Syndromes Patients With Deletion 5q (ASH 2009)
    • Study Finds Vfend A Good Alternative For Fungal Infection Prevention In Myelodysplastic Syndromes
• ►2009 (84)
  • ► December (11)
    • Trisenox May Be Effective In MDS (ASH 2009)
    • Recommended Revlimid Starting Dose Is More Effective Than Low-Dose Revlimid For Myelodysplastic Syndromes (ASH 2009)
    • MDS Patients Are Responsive To Sapacitabine, According To Interim Phase 2 Study Results (ASH 2009)
    • Approved Vidaza Dosing Schedule May Be Better And Safer Than Alternatives (ASH 2009)
    • Beacon NewsFlashes – December 13, 2009
    • Clolar Shows Promise As Myelodysplastic Syndromes Treatment, According To Research Review
    • Phase 2 Study Shows Campath Improves Blood Cell Production For Myelodysplastic Syndromes Patients (ASH 2009)
    • Study Shows Revlimid Reduces Chromosomal Abnormalities For Del-5q Myelodysplastic Syndromes Patients (ASH 2009)
    • The Public Is Encouraged To Comment On Potential Medicare Coverage Of Bone Marrow Transplants For Myelodysplastic Syndromes Patients
    • Velcade May Be Effective In Treating MDS (ASH 2009)
    • Research Validates Possible New Grouping Scheme For MDS Patients Undergoing Stem Cell Transplants
  • ► November (8)
    • Revlimid Alternate-Day Dosing Regimen Shows Promise In Myelodysplastic Syndromes
    • Latest MDS Research To Be Presented At The 51st Meeting Of The American Society Of Hematology (ASH 2009)
    • Reduced-Intensity Drug Regimens Allow Stem Cell Transplantation In Elderly MDS Patients
    • Complication, Acute Pulmonary Failure, Is Associated With Chemotherapy For MDS Patients
    • Ban On Payment For Bone Marrow Donations Challenged In Lawsuit
    • Response After Revlimid Treatment Predicts Risk For AML In Certain Myelodysplastic Syndromes Patients
    • The H1N1 Swine Flu Vaccine And Myelodysplastic Syndromes: A Comprehensive Review
    • Beacon NewsFlashes – November 3, 2009
  • ► October (9)
    • Gene RPS14 Is Linked To Survival Of Patients With Myelodysplastic Syndromes
    • Valproic Acid May Enhance Efficacy Of Vidaza For Myelodysplastic Syndromes
    • Five-Day Intravenous Vidaza For MDS Shows Mixed Results Compared To Standard Dosing Regimen
    • Beacon NewsFlashes - October 15, 2009
    • Personal Perspective: Blogging About Skiing, Golfing, And Airplanes - And Living With MDS
    • Evening Primrose Oil Alleviates Vidaza Injection Site Irritation
    • Study Finds Lower-Risk MDS Patients Benefit From Erythropoietin Treatments
    • Beacon NewsFlashes - October 2, 2009
    • Study Finds Dacogen And Vidaza Better Than Conventional Care For MDS Patients
  • ► September (12)
    • FDA Analyzing Safety Of Exjade In MDS Patients
    • Beacon BreakingNews - FDA Examining Exjade Safety In MDS Patients
    • Smokers At Higher Risk For Developing Myelodysplastic Syndromes
    • Beacon NewsFlashes – September 25, 2009
    • Iron-Reducing Therapy May Extend Lives Of MDS Patients
    • Revlimid Prescribing May Vary For Different Chromosome 5 Abnormalities
    • H1N1 Swine Flu Vaccinations Recommended For Patients With Myelodysplastic Syndromes
    • New Differences Found In Chinese And Western MDS Patients
    • Patients With Myelodysplastic Syndromes Prefer To Be Transfusion-Independent
    • Beacon NewsFlashes – September 8, 2009
    • Different Prognoses Found For MDS Patients With Chromosome 5 Abnormalities
    • Study Reveals One Fifth Of MDS Patients In The U.K. Are Unable To Receive Life-Extending Treatment
  • ► August (9)
    • Beacon NewsFlashes - August 31, 2009
    • Statistical Results Revealed From Study Of MDS Patients In Romania
    • MDS Patients Dependent On Multiple Transfusions Have Shorter Survival Time
    • Canadian Myelodysplastic Syndromes Patient Seeks Help In United States
    • Beacon NewsFlashes – August 13, 2009
    • Vidaza Upgraded To Preferred Treatment For High-Risk MDS Patients
    • Beacon NewsFlashes - August 7, 2009
    • Beacon SiteUpdate – The MDS Beacon Has A New Design
    • United Kingdom May Halt Funding For Vidaza
  • ► July (16)
    • Beacon NewsFlashes – July 27, 2009
    • Treatment Of Myelodysplastic Syndromes With Dacogen May Cause Fluid Build-Up
    • Amifostine Promotes Improved Blood Production In Some Myelodysplastic Syndromes Patients
    • Chromosome Abnormalities May Predict Success Of Chemotherapy On Patients With Myelodysplastic Syndromes
    • Study Suggests Association Between T-cell Imbalance And Response To Immunosuppressive Therapy In MDS Patients
    • Phase 2 Study Shows Immunosuppressive Treatment Is Safe And Effective For Myelodysplastic Syndromes And Aplastic Anemia
    • German Study Emphasizes Importance Of Multiple Tests For MDS Diagnosis
    • Vidaza Most Effective When First-Choice Treatment (ASCO 2009)
    • MDS Patients’ Pretreatment Risk Level Predicts Outcome Of Vidaza Treatments (EHA 2009)
    • Flow Cytometry Useful For Accurately Diagnosing Myelodysplastic Syndromes
    • Stem Cell Transplantation Most Favorable Treatment For Cognitive Function
    • Beacon NewsFlash - July 9, 2009
    • MDS Prevalence May Be Higher Than Previously Thought
    • Vidaza and Dacogen Effective In MDS Patients With Decreased Kidney Function (ASCO 2009)
    • Nplate Effective For Increasing Platelet Counts In MDS Patients (ASCO 2009)
    • Beacon NewsFlashes – July 1, 2009
  • ► June (13)
    • Obesity And Smoking Linked To Myelodysplastic Syndromes
    • Allogeneic Hematopoietic Cell Transplantation Effective For The Elderly (EHA 2009)
    • Transfusion Independence Linked To Increased Vidaza Treatment Cycles (EHA 2009)
    • Beacon NewsFlashes - June 16, 2009
    • Mutated Gene Sequence Linked To Blood Disorders Such As MDS
    • Recurring Sweet Syndrome Linked To MDS
    • Thalidomide Effective In Low-Risk MDS Patients (EHA 2009)
    • Vidaza and Dacogen Improve Overall Survival Of MDS Patients (EHA 2009)
    • Immune System Increasingly Linked To MDS (ISMDS 2009)
    • Personal Perspective: "I Have MDS."
    • Phase 2 Study Shows Combination Therapy Of Zolinza With Idarubicin And High-Dose Cytarabine Effective For MDS (ASCO 2009)
    • Studies Show Improvement With Increased Dacogen Treatment Cycles (ASCO 2009)
    • Study Shows Iron Chelating Properties Of Wheat Grass Juice (ASCO 2009)
  • ► May (6)
    • MDS Treatments Discussed At ASCO’s 45th Annual Meeting (ASCO 2009)
    • Optimizing Epigenetic Therapies For MDS (ISMDS 2009)
    • 10th International Symposium On Myelodysplastic Syndromes Held In Greece
    • Beacon NewsFlashes - May 11, 2009
    • Vidaza, Revlimid Spur Search for New MDS Drugs
    • Welcome To The MDS Beacon